D004358

9 trials

Sponsors

Asano Yoshihiro, Komatsu Yoshito, Hibi Kiyoshi, Jun Hamano, Uchida Hiroyuki

Conditions

Acute gastroenteritis VomittingAortic stenosis, dyslipidemia Aortic stenosis, aortic valve, dyslipidemia, hypercholesterolemia, LDL cholesterolCoronary artery disease with diabetes mellitus coronary artery disease, diabetes mellitus, dyslipidemia, hypertensionNewly Diagnosed Pediatric Acute Promyelocytic Leukemia Acute Promyelocytic LeukemiaSymptomatic Bradyarrhythmias therapy,drug therapyThymic epithelial tumors (thymoma, thymic carcinoma) with a confirmed pathological diagnosis Thymic epithelial tumor, thymic carcinoma, thymomaTreatment-resistant depression depressioncolorectal cancer colorectal cancer

Phase 2

A phase II study of 2nd-line FOLFIRI+aflibercept in patients with colorectal cancer resistant to anti-EGFR chemotherapy (HGCSG1801)

Active, not recruitingJPRN-jRCTs011190006

Komatsu Yoshitocolorectal cancer colorectal cancer

Start: 2020-01-23Target: 41Updated: 2026-06-29

Comparison of anti-atheroslerotic effects between intensified multifactorial intervention and conventional therapy in patients with coronary artery disease and type 2 diabetes

Active, not recruitingJPRN-jRCTs031200359

Hibi KiyoshiCoronary artery disease with diabetes mellitus coronary artery disease, diabetes mellitus, dyslipidemia, hypertension

Start: 2021-11-17Target: 156Updated: 2026-06-29

Survey of treatment with ondansetron for pediatric acute gastroenteritis

Active, not recruitingJPRN-jRCTs031230305

Kishibe ShunAcute gastroenteritis Vomitting

Start: 2023-09-04Target: 100Updated: 2026-06-29

Phase 2 Clinical Trial for Newly Diagnosed Pediatric Acute Promyelocytic Leukemia: AML-P17

RecruitingJPRN-jRCTs031230727

Yuza YukiNewly Diagnosed Pediatric Acute Promyelocytic Leukemia Acute Promyelocytic Leukemia

Start: 2024-03-21Target: 39Updated: 2026-06-29

RecruitingJPRN-jRCTs071240019

Takemoto ShinnosukeThymic epithelial tumors (thymoma, thymic carcinoma) with a confirmed pathological diagnosis Thymic epithelial tumor, thymic carcinoma, thymoma

Start: 2024-07-03Target: 22Updated: 2026-06-29

A Double-Blind, Randomized, Placebo-Controlled Trial of NTC-801F in Patients with Symptomatic Bradyarrhythmias (Phase II)

Active, not recruitingJPRN-jRCT2051250264

Asano YoshihiroSymptomatic Bradyarrhythmias therapy,drug therapy

Start: 2026-05-18Target: 50Updated: 2026-06-29

Phase 3

A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of the Preventive Effect of Naldemedine on Opioid-Induced Constipation

Active, not recruitingJPRN-jRCTs031200397

Jun Hamanoneoplasms Cancer, Opioid induced constipation

Start: 2021-07-02Target: 100Updated: 2026-06-29

effect of EVOlocumab on the progression of moderate Aortic Stenosis trial

RecruitingJPRN-jRCTs031240618

Hibi KiyoshiAortic stenosis, dyslipidemia Aortic stenosis, aortic valve, dyslipidemia, hypercholesterolemia, LDL cholesterol

Start: 2025-02-25Target: 126Updated: 2026-06-29

Unknown Phase

Ketamine administration for treatment-resistant depression

Active, not recruitingJPRN-jRCTs031210124

Uchida HiroyukiTreatment-resistant depression depression

Start: 2021-05-31Target: 34Updated: 2026-06-29

Related Papers

Novel antiemetic effect of naldemedine in patients initiating opioids for cancer pain: A secondary analysis of a randomized clinical trial.

2026-02-18

A phase II clinical trial on the efficacy and safety of carboplatin plus nab-paclitaxel in chemotherapy-naive advanced or recurrent thymic epithelial tumors: protocol of Nab-TET

Journal of Thoracic Disease2025-09-01

The association between amygdalar volume changes and depressive symptom improvements after repeated ketamine infusion in treatment-resistant depression: a double-blind, randomized, placebo-controlled trial with the following open-label study.

2025-08-14

247. DOES EXCITATORY/INHIBITORY BALANCE PREDICT KETAMINE RESPONSE IN TREATMENT-RESISTANT DEPRESSION? A DOUBLE-BLIND RANDOMIZED CONTROLLED TRIAL WITH 1H-MRS

The International Journal of Neuropsychopharmacology2025-08-01

Glutamate plus glutamine to GABA ratio as a predictor of ketamine response in treatment-resistant depression: A double-blind, randomized, open-label extension study.

2025-04-29

A multicenter, prospective phase II trial of second-line aflibercept plus FOLFIRI in patients with metastatic colorectal cancer refractory to anti-EGFR agents (HGCSG1801): Updated analyses.

Journal of Clinical Oncology2025-01-27

Naldemedine for Opioid-Induced Constipation in Patients With Cancer: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial

Journal of Clinical Oncology2024-09-1010 citations

Preventive effect of naldemedine for opioid-induced constipation in patients with cancer starting opioids: A multicenter, double-blinded, randomized, placebo-controlled, phase 3 trial.

Journal of Clinical Oncology2024-06-051 citations

HGCSG1801: A multicenter, prospective, phase II trial of second-line FOLFIRI plus aflibercept in patients with metastatic colorectal cancer (mCRC) refractory to anti-EGFR antibodies.

Journal of Clinical Oncology2024-01-20

Study protocol for HGCSG1801: A multicenter, prospective, phase II trial of second-line FOLFIRI plus aflibercept in patients with metastatic colorectal cancer refractory to anti-EGFR antibodies

Frontiers in Oncology2022-11-091 citations

Rationale and design of a multicenter, double-blinded, randomized, placebo-controlled trial to investigate the effects of naldemedine on opioid-induced constipation for patients with cancer pain: A study protocol

Contemporary Clinical Trials Communications2022-08-042 citations